NCT06008054View on ClinicalTrials.gov

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Esophageal CancerGastric CancerColorectal Cancer
Interventions
DRUG

SI-B003

Administered by intravenous infusion every 3 weeks (Q3W).

DRUG

BL-B01D1

Administered by intravenous infusion for a cycle of 3 weeks.

DRUG

PD-1 Monoclonal Antibody

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY